The posting of sponsored information and content on this page should not be considered an AAFP endorsement or recommendation of the sponsor's products, services, policies, or procedures. The information and opinions expressed on this page are those of the paid sponsors and do not necessarily reflect the view of the AAFP. The AAFP is not responsible for the content of third-party websites linked from this page; moreover, any links on this page to third-party websites where goods or services are advertised are not endorsements or recommendations by the AAFP of the third-party sites, goods, or services.
The following sponsor-developed resources may be of interest:
Provides insights into the evolving drug misuse epidemic – based on analysis of clinician-ordered drug monitoring performed for patients across the United States by Quest Diagnostics.
It's likely that many of your patients may experience drug-nutrient depletions and interactions caused by common prescription drugs. Download the "Common Drug Classes, Drug-Nutrient Depletions, & Drug-Nutrient Interactions" booklet as a reference guide today.
Watch the webinar from Quest Diagnostics on the CDC guideline for when treating chronic pain. It includes 12 recommendations that prescribers should understand.
New survey data1 reveals the critical role of family practitioners in shaping patient statin knowledge. As family physicians, you’re on the front lines of treating common ailments ranging from fevers to fibromyalgia, cataracts to cancer, and everything in between, including America’s number one killer—heart disease. You may be familiar with this scenario: a patient with high cholesterol, at risk for heart disease, stops taking the statin that you prescribed, blaming muscle pain, forgetfulness, or cost of monthly prescription. It’s not just you. Data shows that at least 50% or more of people on a statin medication discontinue it within one year after treatment2, so many other doctors may be experiencing the same frustration that their patients are stopping this life-saving medication. To motivate patients to work with their doctors and “speak up before they stop their statin,” a new educational initiative—“Take Cholesterol to Heart”—recently launched in partnership with the AAFP Foundation and Kowa Pharmaceuticals America, Inc. The initiative was informed by the results of a new Harris Poll survey —commissioned by Kowa Pharmaceuticals America, Inc.—of more than 5,000 cholesterol patients, including polypharmacy patients and those with common comorbidities to heart disease. ACTION: The Statin Survey found that 82% of patients were first diagnosed by their family physician or internist, highlighting the pivotal role family doctors play in shaping patients’ knowledge and mindset towards statins. The survey also found that 59% of patients say it’s extremely important to them that their provider takes an individualized approach to selecting the right statin for them.
In the sixth edition of the Health Trends™ Prescription Drug Monitoring Report: Prescription Drug Misuse in America, Quest Diagnostics presents an analysis of prescription drug use and misuse rates in the United States based on 3.4 million de-identified prescription drug monitoring test results performed by Quest Diagnostics between 2011 and 2016.
Drug testing provides the only objective measure by which health care providers gather information regarding patient use or non-use of drugs. Through this clinical educational webinar, viewers will learn about the scope, and limitations, of presumptive and definitive drug testing methods. Viewers will gain insight into how to appropriately utilize both presumptive and definitive drug testing, and how to rule out false-positive results.
Asthma Today is a resource for asthma patients and their families created by the American Thoracic Society and supported by an educational grant from GlaxoSmithKline. The e-booklet discusses asthma symptoms, diagnosis, and treatments, and features the latest research on asthma presented at the ATS 2017 International Conference.
According to the U.S. Department of Health and Human Services, 60 to 70 million Americans are affected by digestive issues. A growing body of research suggests that consumption of probiotics, known as the “good” bacteria that naturally exist in the digestive system, can help support a healthy digestive system. Specifically, probiotics may help support regularity of bowel movements, a healthy gut microflora, and digestive health during travel. The production and absorption of certain nutrients in the colon may also be enhanced by probiotics. Learn more about probiotics, common species, and what to look for on probiotic product labels.
4.6 years and nearly 5 doctor visits. That is what the American Autoimmune Related Diseases Association reports it takes on average to receive a proper autoimmune disease diagnosis. Laboratory testing correlated with clinical findings is key to differential diagnosis, disease classification and better patient care for these challenging diseases. Through this clinical education bulletin, you will learn about the clinical benefits of a new advanced diagnostic test panel offered by Quest Diagnostics—ANA Screen, IFA, Reflex to Titer/Pattern, and Reflex to the 11 Antibody Cascade with IdentRA®. This comprehensive panel starts with the highly sensitive ANA IFA screen—the American College of Rheumatology gold standard—followed by 3 tiers of specific autoantibody testing. Testing through a 3-tiered algorithm can be an effective way to help make an early and differential diagnosis of the 8 most common rheumatic diseases. This may help speed evaluation for early diagnosis of autoimmune diseases and better patient outcomes.
Though colonoscopy is the gold standard for diagnosing IBD, routine use is not warranted as it is costly, invasive, and associated with low-but-measurable morbidity. Calprotectin may be used as one of the initial tests in patients with suspected IBD. Calprotectin has three important clinical uses: 1) Diagnose inflammatory bowel disease (IBD) 2) Differentiate IBD from irritable bowel syndrome (IBS) 3) Monitor patients with IBD for treatment response and relapse Calprotectin is a small calcium-binding protein that makes up about 60% of neutrophil cytosol protein content. During inflammation, neutrophils migrate to the intestinal mucosa, and calprotectin is leaked into the bowel lumen. Numerous studies have shown that stool calprotectin concentration can help diagnose IBD, and distinguish it from IBS and other conditions with a similar presentation. In a 2010 meta-analysis, elevated stool calprotectin demonstrated a sensitivity of 93%, and a specificity of 96% for differentiating IBD from other causes of GI symptoms in adults. In children and teenagers, the sensitivity is 92% and the specificity is 76%. Calprotectin may be used as one of the initial tests in patients with suspected IBD; levels can help avoid unnecessary colonoscopy, as normal levels are not typically associated with active IBD. Conversely, levels above normal are consistent with organic diseases such as IBD and colorectal cancer, and warrant consideration of colonoscopy.